Multiple Aesthetic Clinics Ordered to Self-Inspect Hydroxyapatite Products; Regenerative Medicine Firm NuoYi MaiEr Raises Nearly RMB 300 Million in Series C; Livzon Group Reports Smooth Progress on Semaglutide Injection Development

Recently, Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd. announced the completion of a nearly 300 million yuan C-round financing. This round of financing was led by the New Materials Fund for the Transformation and Upgrading of Manufacturing under Shenzhen Capital Group, with participation from some existing shareholders and management. WinX Capital served as the exclusive financial advisor for this round of financing.

Neo Modulus stated that the funds from this round of financing will mainly be used for the commercial promotion, clinical trials, and implementation of international strategies for the company's multiple innovative medical device products.

Data shows that Neo Modulus was founded in March 2017 as an innovative enterprise specializing in the research, development, production, and commercialization of regenerative implantable medical devices.(Source of information:(Caijing.com)

Question from Investors:

The review progress of the company's Semaglutide has been suspended. What is the reason? Does the company have any relevant information? Secretary Dong answers (Livzon Group (35.540, -0.17, -0.48%) SZ000513):

Dear investors, hello! The research and development as well as the application for semaglutide injection are proceeding smoothly: the Type II diabetes indication has been submitted for production; the weight loss indication has completed Phase III clinical trial enrollment. Please be informed. Thank you!(Source of information:Ask the Secretary of the Board )

Medical aesthetics industry insiders revealed that around January 14, some medical aesthetics institutions had already received notices from relevant regulatory authorities, requiring them to self-inspect whether they use hydroxyapatite-related products and whether the products in use are legal. If such products are used, they need to report promptly to ensure no safety issues arise. According to circulated information within the industry, a certain region in Hubei Province issued an internal notice requiring medical institutions to carefully review relevant materials, tally the usage of hydroxyapatite-related products, and submit statistical reports by the day after the notice was issued.(Source of information:21st Century Business Herald )